{"schema_version":"secwatch.filing_event.v1","accession":"0001999371-25-015796","form_type":"8-K","ticker":"TNXP","cik":"0001430306","company_name":"Tonix Pharmaceuticals Holding Corp.","filed_at":"2025-10-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.392345+00:00","generated_at":"2026-05-17T02:43:04.963926+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Tonix doses first patient in FOCUS study of intranasal oxytocin for AVP-D at MGH","bullets":["First patient dosed in FOCUS study at Massachusetts General Hospital for arginine-vasopressin deficiency (AVP-D).","Randomized, double-blind, placebo-controlled crossover pilot evaluating TNX-2900 (6 IU) and TNX-1900 (24 IU).","Primary endpoints: markers of anxiety, depression, and socioemotional functioning; exploratory 2-week replacement on mental health.","Study aims to generate preliminary data for future oxytocin replacement therapy in AVP-D.","TNX-1900/TNX-2900 are intranasal Mg2+-potentiated oxytocin formulations in development for multiple conditions."],"urls":{"canonical":"https://secwatch.observer/filing/0001999371-25-015796","json":"https://secwatch.observer/filing/0001999371-25-015796.json","markdown":"https://secwatch.observer/filing/0001999371-25-015796.md","text":"https://secwatch.observer/filing/0001999371-25-015796.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1430306/000199937125015796/0001999371-25-015796-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1430306/000199937125015796/tnxp_8k-102225.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T02:43:04.963926+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}